Speakers

Thomas L. Ortel, MD, PhD
Chief, Division of Hematology
Director, Anticoagulation Management Service
Director, Clinical Coagulation and Platelet Immunology Laboratories
Duke University Medical Center, Durham, NC

Mark Triscott, PhD
Vice President of R&D, Reagent Development and Sensors
Instrumentation Laboratory, Bedford, MA

Date
Wednesday, July 31, 2013

Time
7:00–8:30 a.m.

Location
Hilton Americas-Houston
Grand Ballroom I

Credits
1.5 CE credits will be offered through ACCENT® or P.A.C.E.®
**Speaker Bios**

**Thomas L. Ortel, MD, PhD**

Dr. Ortel is a Professor of Medicine and Pathology and the Director for Laboratory Research in the Department of Medicine at Duke University Medical Center. He is also the Medical Director of the Anticoagulation Management Service and the Director of the Duke Clinical Coagulation and Platelet Immunology Laboratories. He received his MD and PhD from the Indiana University School of Medicine in Indianapolis and completed a residency in Internal Medicine and a fellowship in Hematology/Oncology at Duke University Medical Center. He has published more than 170 articles in journals including the *New England Journal of Medicine*, *Blood*, *Journal of Thrombosis and Haemostasis*, and *Nature*. He is currently the Principal Investigator for clinical research trials investigating thrombotic disorders and oral anticoagulation therapies, supported by the National Heart, Lung, and Blood Institute; the Centers for Disease Control and Prevention (CDC); in addition to industry sources.

**Mark Triscott, PhD**

With more than 20 years of experience in Hemostasis diagnostics, Dr. Triscott has led the research and development effort for over 50 assays, 510(k)-cleared by the FDA and commercialized across several testing platforms. His work has been featured in over 20 peer-reviewed publications such as *Thrombosis Research*, *Anesthesiology*, and *Journal of Biological Chemistry*, and he has authored/contributed to more than 75 published abstracts. In addition, he authored three patents in U.S. and foreign filings for Hemostasis assays, including Fibrinolytic and Thrombin-based reagents. He has studied high-sensitivity immunoassays at the CDC and is a “subject matter expert” on Design Control in ISO 13485. Dr. Triscott joined the executive group at IL in 2006. He holds a BSc (Hons1) and PhD in Microbiology from the University of Queensland in Australia and trained in Molecular Biology at Wake Forest University, North Carolina.


For questions and registration assistance, contact your IL sales representative. Space is limited. This event is free to attend. Early arrival is recommended.
ANTIPHOSPHOLIPID SYNDROME: Guidelines for Laboratory Testing

Description

Antiphospholipid Syndrome (APS) is one of the most common autoimmune diseases, causing venous, arterial/small-vessel thrombosis, and pregnancy complications.1 Prompt and accurate diagnosis is critical in determining optimal patient management strategies. Symptoms are frequently associated with several other disorders, resulting in underutilized or incorrect use of antiphospholipid (aPL) antibody testing.

Dr. Ortel will propose clinical indicators for effectively profiling APS patients and review laboratory testing methods for Lupus Anticoagulants (LA) and aPL antibodies. Dr. Triscott will discuss LA and APS testing methodologies. An automated Hemostasis specialty testing system will be demonstrated.

Presentation Topics

- Clinical significance and classification criteria for APS
- Testing guidelines for LA and aPL
- Strategies for optimizing aPL detection and testing standardization
- Recommendations for results interpretation
- Product demonstration of an automated Hemostasis testing platform for APS

1. Antiphospholipid Syndrome Foundation of America, Inc.
Register to attend

at www.ilus.com/workshop

by July 29, 2013.

For questions and registration assistance, contact your IL sales representative. Space is limited. This event is free to attend. Early arrival is recommended.